Parison Amy sold $2K of EDIT

Parison Amy (SVP, Chief Financial Officer) sold 678 shares of Editas Medicine, Inc. (EDIT) at $2.58 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parison Amy
Published Aug 5, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EDIT
Neutral
low confidence
Mentioned
$EDIT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EDITNeutralLow
01

Why it matters

The newest fact is the CFO’s planned open-market sale details (shares, price, total value, and post-sale holdings).

02

Market read

Traders may note insider selling, but the transaction size and 10b5-1 framing suggest limited trading significance absent other catalysts.

03

What to watch

The article does not provide context on total insider holdings beyond the post-transaction figure, nor does it indicate any concurrent buys or other corporate developments.

Relevance 2/10Novelty 2/10Timing: filed after-hours on 2026-08-05, covering a sale dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Editas Medicine, Inc.

Company-level read

Ticker impact

$EDITNeutralLow confidence
Context

Editas Medicine CFO Parison Amy filed a Form 4 open-market sale of 678 shares at $2.58 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any effect is short-lived unless accompanied by other news.

Evidence & confidence

The filing is a routine 10b5-1 planned sale with small dollar value ($1,749.24) relative to typical market moves, and the article provides no new operational or financial catalyst.

Market effects

No sector read-through; this is a single planned insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • Editas Medicine, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Parison Amy

    SVP and Chief Financial Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EDITMed

Editas Medicine Reports Q3 2026 Results, $10.4M Revenue and $23.4M Net Loss

Editas Medicine reported Q3 2026 revenue of $10.4M and a net loss of $23.4M, improving from the same period last year. The company received Australian clearance for its Phase 1/2 Strive study of EDIT-401 and expects to dose the first patients this year. Editas anticipates its cash resources will fund operations into the second half of 2028. Preclinical data for EDIT-401 showed promising results in non-human primates.

$PRMEHighAI 8/10

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.